oxychlorosene and Cystitis--Interstitial

oxychlorosene has been researched along with Cystitis--Interstitial* in 7 studies

Trials

1 trial(s) available for oxychlorosene and Cystitis--Interstitial

Article	Year
Efficacy of Clorpactin in refractory bladder pain syndrome/interstitial cystitis: a randomized controlled trial. International urogynecology journal, 2021, Volume: 32, Issue:5 Clorpactin is an antibacterial agent with limited evidence for its use as instillation therapy in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). This was a multi-centre, single-blinded randomized controlled trial to investigate whether Clorpactin instillation results in symptom improvement in patients with refractory BPS/IC.. Fifty women with refractory BPS/IC were randomized to undergo cystoscopy/hydrodistension (25) or instillation of Clorpactin 0.4% solution (25) under general anaesthesia. Primary outcome was based on Global Response Assessment (GRA) at 3 months; secondary outcomes were based on O'Leary Sant Symptom (OLSI) and Problem (OLPI) questionnaire scores, visual analogue scale (VAS) score for pain and bladder diary parameters.. Complete follow-up data were available on 22 in the hydrodistension group and 16 in the Clorpactin group. GRA improvement was 4.5% for hydrodistension and 56% for Clorpactin (p = 0.001) at 3 months. Reduction in mean total scores for OLSI (14.1 to 9.1; p = 0.004) and OLPI (12.6 to 7.4; p = 0.001) was seen in the Clorpactin group only. VAS pain scores were reduced in the Clorpactin group only (7.4 to 3.3; p < 0.001). Post-treatment VAS pain scores did not differ between groups although 6/25 (24%) women in the Clorpactin group required admission for pain compared to 1/25 (4%) in the hydrodistension group.. Clorpactin treatment results in significant improvement in BPS/IC symptoms, bother and pain based on the GRA, OLSI/OLPI and VAS pain scores at 3 months post-treatment compared to cystoscopy/hydrodistension. These conclusions are limited by the high loss to follow-up in both groups. Topics: Administration, Intravesical; Benzenesulfonates; Cystitis, Interstitial; Female; Humans; Pain Measurement; Pelvic Pain; Treatment Outcome	2021

Article

Year

Efficacy of Clorpactin in refractory bladder pain syndrome/interstitial cystitis: a randomized controlled trial.

International urogynecology journal, 2021, Volume: 32, Issue:5

Clorpactin is an antibacterial agent with limited evidence for its use as instillation therapy in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). This was a multi-centre, single-blinded randomized controlled trial to investigate whether Clorpactin instillation results in symptom improvement in patients with refractory BPS/IC.. Fifty women with refractory BPS/IC were randomized to undergo cystoscopy/hydrodistension (25) or instillation of Clorpactin 0.4% solution (25) under general anaesthesia. Primary outcome was based on Global Response Assessment (GRA) at 3 months; secondary outcomes were based on O'Leary Sant Symptom (OLSI) and Problem (OLPI) questionnaire scores, visual analogue scale (VAS) score for pain and bladder diary parameters.. Complete follow-up data were available on 22 in the hydrodistension group and 16 in the Clorpactin group. GRA improvement was 4.5% for hydrodistension and 56% for Clorpactin (p = 0.001) at 3 months. Reduction in mean total scores for OLSI (14.1 to 9.1; p = 0.004) and OLPI (12.6 to 7.4; p = 0.001) was seen in the Clorpactin group only. VAS pain scores were reduced in the Clorpactin group only (7.4 to 3.3; p < 0.001). Post-treatment VAS pain scores did not differ between groups although 6/25 (24%) women in the Clorpactin group required admission for pain compared to 1/25 (4%) in the hydrodistension group.. Clorpactin treatment results in significant improvement in BPS/IC symptoms, bother and pain based on the GRA, OLSI/OLPI and VAS pain scores at 3 months post-treatment compared to cystoscopy/hydrodistension. These conclusions are limited by the high loss to follow-up in both groups.

Topics: Administration, Intravesical; Benzenesulfonates; Cystitis, Interstitial; Female; Humans; Pain Measurement; Pelvic Pain; Treatment Outcome

2021

Other Studies

6 other study(ies) available for oxychlorosene and Cystitis--Interstitial

Article	Year
Commentary: Efficacy of Clorpactin in refractory bladder pain syndrome/interstitial cystitis: a randomized controlled trial. International urogynecology journal, 2021, Volume: 32, Issue:5 Topics: Benzenesulfonates; Cystitis, Interstitial; Double-Blind Method; Humans	2021
Chlorpactin instillation releases calcitonin gene-related peptide in interstitial cystitis patients. Urology, 2001, Volume: 57, Issue:6 Suppl 1 Topics: Adult; Aged; Benzenesulfonates; Calcitonin Gene-Related Peptide; Cystitis, Interstitial; Dilatation; Female; Humans; Middle Aged; Surface-Active Agents	2001
Use of clorpactin WCS 90 for relief of symptoms due to interstitial cystitis. The Journal of urology, 1957, Volume: 77, Issue:3 Topics: Anti-Infective Agents, Local; Benzenesulfonates; Cystitis; Cystitis, Interstitial; Halogens; Hydrocarbons, Halogenated	1957
Treatment of interstitial cystitis with clorpactin. Postgraduate seminar. American Urological Association. North Central Section, 1957 Topics: Anti-Infective Agents, Local; Benzenesulfonates; Cystitis; Cystitis, Interstitial; Halogens; Hydrocarbons, Halogenated	1957
Use of clorpactin WCS 90 for relief of symptoms due to interstitial cystitis. Transactions of the American Association of Genito-Urinary Surgeons, 1956, Volume: 48 Topics: Anti-Infective Agents, Local; Benzenesulfonates; Cystitis; Cystitis, Interstitial; Halogens; Hydrocarbons, Halogenated	1956
Clorpactin WCS-90 in the treatment of interstitial cystitis. Quarterly bulletin. Northwestern University (Evanston, Ill.). Medical School, 1955, Volume: 29, Issue:4 Topics: Anti-Infective Agents, Local; Benzenesulfonates; Cystitis; Cystitis, Interstitial; Halogens; Hydrocarbons, Halogenated	1955